ANB033

Beyond's analysis on ANB033

• 2026-10-11 — First Tracks Biotherapeutics scheduled to release critical Phase 1b clinical data for celiac disease treatment

Recent news mentioning ANB033

• 2026-10-11 — First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026

Appears alongside

• CD122

Browse the full archive →